News & Updates

Show Multimedia Only

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

15 Dec 2024

Patients with chronic obstructive pulmonary disease (COPD) are at heightened risk of myocardial infarction (MI) and pulmonary embolism (PE) in the presence of acute exacerbations, according to a study.

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

15 Dec 2024

Criteria used affects diagnostic outcome in fevers of unknown origin

15 Dec 2024

Applying either the qualitative or the quantitative criteria of fever of unknown origin (FUO) appears to over- or underestimate infectious diseases and undiagnosed illnesses when using an International Classification of Diseases, 10th edition (ICD-10)-adjusted FUO five-category system.

Criteria used affects diagnostic outcome in fevers of unknown origin

15 Dec 2024

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

15 Dec 2024

In the treatment of patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) do not contribute to an increased risk of intracranial haemorrhage compared with antiplatelet therapy, according to the results of a systematic review and meta-analysis.

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

15 Dec 2024

Salbutamol may lower risk, improve prognosis of prostate cancer

14 Dec 2024

The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.

Salbutamol may lower risk, improve prognosis of prostate cancer

14 Dec 2024

$Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma$

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

14 Dec 2024

Dual inhibition of EZH1/2 with valemetostat appears to induce responses in patients with relapsed or refractory peripheral T-cell lymphoma while having a manageable safety profile, according to the results of a single-arm phase II trial.

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

14 Dec 2024

Elafibranor improves transplant-free survival in patients with PBC

14 Dec 2024 by

Among patients with primary biliary cholangitis (PBC), treatment with elafibranor improved predicted transplant-free survival rates based on improvements in GLOBE and UK-PBC scores, according to the phase III ELATIVE trial presented at The Liver Meeting 2024.

Elafibranor improves transplant-free survival in patients with PBC

14 Dec 2024

Risk of myasthenia gravis onset highest in first month after statin initiation

14 Dec 2024 by

A study investigating the association between the risk of myasthenia gravis (MG) and statin therapy found the risk of onset in patients with no prior history of MG and the risk of exacerbation among patients with pre-existing MG were the highest in the first month after initiating statins.

Risk of myasthenia gravis onset highest in first month after statin initiation

14 Dec 2024

Physically active children have healthier retinal vasculature

14 Dec 2024 by

The Hong Kong Children Eye Study in nearly 12,000 local children aged 6–8 years shows that increased physical activity is associated with healthier retinal microvasculature.

Physically active children have healthier retinal vasculature

14 Dec 2024

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

13 Dec 2024 by

In patients with type 2 diabetes (T2D), treatment with empagliflozin has a null effect on the risk of nonproliferative diabetic retinopathy (NPDR) compared with a DPP-4 inhibitor but may confer protection against DR progression, according to a study.

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

13 Dec 2024

Belzutifan 120 mg on par with higher dose in advanced clear cell RCC

13 Dec 2024

Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.

Belzutifan 120 mg on par with higher dose in advanced clear cell RCC

13 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

Criteria used affects diagnostic outcome in fevers of unknown origin

Criteria used affects diagnostic outcome in fevers of unknown origin

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

Salbutamol may lower risk, improve prognosis of prostate cancer

Salbutamol may lower risk, improve prognosis of prostate cancer

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

Elafibranor improves transplant-free survival in patients with PBC

Elafibranor improves transplant-free survival in patients with PBC

Risk of myasthenia gravis onset highest in first month after statin initiation

Risk of myasthenia gravis onset highest in first month after statin initiation

Physically active children have healthier retinal vasculature

Physically active children have healthier retinal vasculature

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

Belzutifan 120 mg on par with higher dose in advanced clear cell RCC

Belzutifan 120 mg on par with higher dose in advanced clear cell RCC